General Information of Drug (ID: DM5YHJ2)

Drug Name
KW-2170 Drug Info
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
3075774
CAS Number
CAS 207862-44-0
TTD Drug ID
DM5YHJ2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting DNA topoisomerase II (TOP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [3]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [4]
Teniposide DMLW57T Acute lymphoblastic leukaemia 2A85 Approved [3]
Mitoxantrone DMM39BF Acute myelogenous leukaemia 2A41 Approved [5]
Idarubicin DMM0XGL Acute myelogenous leukaemia 2A41 Approved [3]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [3]
Lomefloxacin DMVRH9C Bacterial infection 1A00-1C4Z Approved [6]
Dexrazoxane DMD7X1O Breast cancer 2C60-2C65 Approved [3]
Podofilox DMT2EJP Condyloma 1A95 Approved [7]
Enoxacin DMYTE6L Acute gonococcal cervicitis Approved [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004178)
2 KW-2170 (Kyowa Hakko Kogyo). IDrugs. 2002 Oct;5(10):1000-3.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
5 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
6 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
7 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
8 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.